#USA #New York #Pomerantz LLP #Skye Bioscience #nimacimab

Investor Alert: Legal Investigation into Skye Bioscience Inc.

Investors in Skye Bioscience, Inc. (NASDAQ: SKYE) are currently facing significant concerns over the company’s latest trial results, which have led to a dramatic decline in stock value. Pomerantz LLP, a renowned law firm with a long-standing reputation for representing victims of corporate misconduct, is taking steps to investigate these troubling developments.

The investigation arises in response to claims that Skye Bioscience and several of its executives may have engaged in securities fraud or committed other unlawful acts concerning the company's business practices. Investors who have suffered losses are encouraged to reach out to Pomerantz LLP's Danielle Peyton to discuss potential claims.

Recent Developments

On October 6, 2025, Skye Bioscience announced the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study involving nimacimab, a peripherally-restricted CB1 inhibitor antibody. The results were far from what stakeholders had hoped for. The report confirmed that the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to the placebo group. Furthermore, early pharmacokinetic analyses indicated lower than anticipated drug exposure, suggesting that higher dosages might be necessary for effective results.

In immediate response to this discouraging news, Skye’s stock plummeted significantly—by $2.85 per share or a staggering 60%, closing at just $1.90 per share. This steep downturn has rocked investor confidence, and many are seeking legal counsel to evaluate their rights and options moving forward.

About Pomerantz LLP

Pomerantz LLP has been a major player in the landscape of class action litigation for over 85 years. Founded by Abraham L. Pomerantz, the firm is well-regarded for its efforts in securing compensation for victims of securities fraud and corporate malfeasance. Their team, which operates across multiple locations including New York, Chicago, and London, aims to uphold investor rights and financial integrity.

The firm’s history in handling securities class actions has made it a go-to resource for investors looking to navigate the murky waters of financial loss due to misconduct. To date, Pomerantz LLP has managed to obtain numerous multimillion-dollar settlements for clients affected by unethical corporate practices.

Investor Guidance

In light of these developments, it is crucial for affected investors to be proactive. Pomerantz LLP emphasizes the importance of reaching out to their firm to discuss the situation as it pertains to individual cases. Investing time in understanding these legal rights can prove beneficial for those seeking to recover losses incurred due to Skye’s recent performance. Interested individuals may contact Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980.

In a world where corporate actions significantly affect investors, Pomerantz LLP is stepping in to advocate for those who feel wronged. The firm’s commitment to challenging corporate wrongdoing continues to empower shareholders, allowing them to assert their rights against potential fraud or misconduct. As the situation surrounding Skye Bioscience unfolds, it remains a pivotal moment for investors caught up in this turbulent scenario.